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Opinion
Novel Mechanistic Insights into Viral Modulation of
Immune Receptor Signaling
Alexander B. Sigalov*
Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
To successfully infect, replicate, and
persist in the host, viruses have evolved
numerous strategies to take control of
multiple cellular processes, including those
that target transmembrane (TM) signal
transduction mediated by immune recep-
tors. Despite tremendous advancement in
recent years, the exact molecular mecha-
nisms underlying these critical points in
viral pathogenesis remain unknown. In
this Opinion, based on a novel model of
immune signaling, the Signaling Chain
HOmoOLigomerization (SCHOOL)
model, I suggest specific mechanisms used
by different viruses such as human immu-
nodeficiency virus (HIV), cytomegalovirus
(CMV), severe acute respiratory syndrome
coronavirus (SARS-CoV), herpesvirus sai-
miri (HVS), human herpesvirus 6 (HHV-
6), etc., to modulate the host immune
response mediated by members of the
family of multichain immune recognition
receptors (MIRRs). I also demonstrate
how the SCHOOL model, together with
the lessons learned from viral pathogene-
sis, can be used practically for rational
drug design and the development of new
therapies for immune disorders.
In MIRRs, the recognition domains
and signaling sequences containing immu-
noreceptor tyrosine-based activation mo-
tifs (ITAMs) are located on separate
subunits bound together by noncovalent
TM interactions (Figure 1A) [1–3]. Based
on a novel biophysical phenomenon, the
homointeractions of intrinsically disor-
dered proteins [4,5], the SCHOOL model
of MIRR signaling [3,6–8] uncovers the
molecular mechanisms by which clustering
of the extracellular recognition domains
leads to receptor triggering. The model
suggests that MIRR engagement leads to
receptor oligomerization coupled with a
multi-step structural reorganization driven
by the homooligomerization of signaling
subunits (Figure 1B). Importantly, this
model is based on specific protein–protein
interactions—biochemical processes that
can be influenced and controlled, provid-
ing a promising drug design approach [9].
Within the model, specific blockade or
disruption of TM interactions causes a
physical and functional disconnection of
the MIRR subunits (Figure 1C)
[6,7,10,11]. Antigen stimulation of these
‘‘predissociated’’ receptors leads to reori-
entation and clustering of the recognition
but not signaling subunits. As a result,
signaling oligomers are not formed, ITAM
Tyr residues do not become phosphory-
lated, and the signaling cascade is not
initiated (Figure 1C). In contrast, this
‘‘predissociation’’ does not prevent the
formation of signaling oligomers when
signaling subunits are clustered by specific
antibodies that trigger cell activation (not
illustrated).
Predicted and molecularly explained by
the SCHOOL model [7,10–13], manipu-
lation of MIRR signaling is performed by
numerous unrelated viruses throughout
their life cycle. In this context, the ability
viruses have developed over centuries of
evolution [13,14] to modulate T cell
receptor (TCR) signaling plays a crucial
role in viral pathogenesis. For T lympho-
tropic viruses, the virus may inhibit TCR
signaling to disarm the receptor and
successfully enter the cell [7,10,11,13,14].
A similar strategy can be used by the virus
to persist in the cell until it reactivates and
produces infectious particles. For other
viruses, modulation of TCR signaling can
be used to inhibit the T cell response to
infected cells [7,11,13,14]. Structurally,
TCR is a member of the MIRR family
and has the a and b antigen-binding
subunits that are bound by electrostatic
TM interactions with three signaling ho-
mo- and heterodimers: ff, CD3ed, and
CD3ec (Figure 2A) [2,15]. As suggested by
the SCHOOL model [7,10,11,13], these
interactions are not only promising thera-
peutic targets, but also represent an impor-
tant point of viral attack.
TM peptides capable of inhibiting
TCR-mediated cell activation were first
reported in 1997 [16]. The vast majority
of findings were reported for the TCR
core peptide (CP), a synthetic peptide
corresponding to the sequence of the
TCRa TM domain (TMD) and known
to interact with the TMDs of CD3de and f
[2,15]. Interestingly, T cell activation via
anti-CD3 antibodies is not affected by this
peptide (Table 1). As shown, TCR CP
might be a proper treatment for human T
cell-mediated dermatoses substituting for
corticosteroids [17,18]. However, despite
extensive studies [2,17–28], the mode of
action of this clinically relevant peptide
was not explained until 2004 when the
SCHOOL model was first introduced [6].
Recently, inhibition of T cell activation
has been reported for the fusion peptide
(FP) found in the N terminus of the HIV
envelope glycoprotein 41 (gp41) [29,30].
These data are the first to demonstrate that
not only does FP function to fuse the virion
with the host cell membrane [31,32], but it
also has immunomodulatory activity. The
peptide inhibits antigen- but not anti-CD3-
stimulated T cell activation in vitro and has
immunosuppressive activity in mice [29]
(Table 1). Similar to TCR CP
[18,20,22,23], HIV FP has been suggested
for the treatment of T cell-mediated
pathologies [29]. However, the mode of
action of this peptide remained unex-
plained until 2006 when the SCHOOL
model was first applied to this area [7].
Considering the similarity between FP
and CP in patterns of immunomodulatory
Citation: Sigalov AB (2009) Novel Mechanistic Insights into Viral Modulation of Immune Receptor
Signaling. PLoS Pathog 5(7): e1000404. doi:10.1371/journal.ppat.1000404
Editor: Marianne Manchester, The Scripps Research Institute, United States of America
Published July 31, 2009
Copyright:  2009 Alexander B. Sigalov. This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.
Funding: This study was supported in part by the National Institutes of Health (http://www.nih.gov/; project
R21-AI074616). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The author has declared that no competing interests exist.
* E-mail: Alexander.Sigalov@umassmed.edu
PLoS Pathogens | www.plospathogens.org 1 July 2009 | Volume 5 | Issue 7 | e1000404
activity (Table 1) and in their having two
electropositive residues in their primary
sequences, the SCHOOL model reason-
ably suggests a similar mode of action for
these peptides (Figure 2) [3,6,7,10–12].
Briefly, CP and FP compete with TCRa
for binding to CD3de and ff, resulting in
functional disconnection of these subunits
(Figure 2C). This prevents formation of
CD3de and f signaling oligomers and thus
inhibits T cell activation upon stimulation
with antigen but not anti-CD3 antibodies
(Figure 2D), thereby suggesting a molecu-
lar explanation for the use of OKT3
antibodies in HIV therapy to augment
immune activation [33]. Interestingly, the
SCHOOL mechanism is the only one
consistent with all of the experimental data
on the immunomodulatory action of HIV
FP and TCR CP reported so far
[16,21,24–26,28–30].
Charge distribution patterns for fusion
protein regions are surprisingly conserved
in many unrelated viruses and show
similarities to those for TCR CP and
HIV FP (Figure 2E). Thus, it is highly
probable that these proteins would also
target the TCR TM interactions using the
SCHOOL mechanism. Exploratory se-
quence investigation of FPs from SARS-
CoV, Lassa virus (LASV), lymphocytic
choriomeningitis virus (LCMV), Mopeia
virus (MOPV), and Tacaribe virus
(TACV) reveals a close similarity in the
positioning of the electropositive residues
(Figure 2E). Intriguingly, analysis of other
unrelated viruses has yielded similar cor-
relations in primary structure and func-
tion. Earlier studies have reported an
inhibitory effect on lymphocyte prolifera-
tion by CKS-17 peptide, a synthetic 17-
mer peptide with sequence corresponding
to a highly conserved region of TM
proteins of human and animal retrovirus-
es, including the TM protein gp21 of
human T lymphotropic virus type 1
(HTLV-1) [34–36]. Interestingly, peptides
corresponding to regions of HIV TM
protein gp41 homologous to the highly
conserved and immunosuppressive se-
quence contained within the TM proteins
p15E and gp21 of animal and human
retroviruses, respectively, also have been
reported to inhibit lymphoproliferation
Figure 1. Novel model of immune signaling reveals a new target and tools for immunomodulatory intervention. (A) Multichain
immune recognition receptor (MIRR) assembly. Binding and signaling subunits are shown in red and green, respectively. ITAMs are shown as orange
rectangles. Transmembrane interactions between MIRR ligand-binding and signaling components (shown by solid arrow) play a key role in receptor
assembly and integrity on resting cells. (B) The signaling chain homooligomerization (SCHOOL) model, which proposes that the homooligomerization
of signaling subunits plays a central role in triggering MIRRs. Small solid black arrows indicate specific intersubunit hetero- and homointeractions
between transmembrane and cytoplasmic domains, respectively. Circular arrow indicates ligand-induced receptor reorientation. All interchain
interactions in a dimeric intermediate are shown by dotted black arrows reflecting their transition state. Phosphate groups are shown as dark circles.
(C) Molecular mechanisms underlying proposed immunomodulatory intervention by transmembrane-targeted agents. Specific blockade of
transmembrane interactions between MIRR recognition and signaling subunits results in ‘‘predissociation’’ of the receptor complex, thus preventing
formation of signaling oligomers and inhibiting ligand-dependent immune cell activation. In contrast, stimulation of these predissociated MIRRs with
cross-linking antibodies to signaling subunits should still lead to receptor triggering and cell activation (not shown).
doi:10.1371/journal.ppat.1000404.g001
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Figure 2. Molecular mechanisms suggested by the SCHOOL model to be used by diverse viruses to modulate TCR signaling. (A) TCR
assembly. The a and b binding subunits are shown in red. The CD3e, CD3d, CD3c, and f signaling subunits are shown in green. ITAMs are shown as
orange rectangles. Within the SCHOOL model, transmembrane-targeted agents such as TCR core peptide (CP) or HIV gp41 fusion peptide (FP) disrupt
the transmembrane electrostatic interactions between the ligand-binding TCRa chain and CD3de and ff by competing with the TCRa chain for
binding to CD3de and ff (B). This results in functional disconnection of the relevant signaling subunits ([C], shown as a simplified axial view) and
prevents formation of signaling oligomers upon antigen but not antibody stimulation, thus inhibiting antigen-mediated but not anti-CD3-mediated
TCR triggering and cell activation (D). Primary sequence analysis of proven and predicted immunomodulatory sequences of viral fusion protein
regions and other domains shows a similarity in the charge distribution pattern with two essential positively charged residues (shown in blue) spaced
apart by three to four or seven to eight amino acids (E), suggesting a similarity of mechanisms used by diverse viruses in their pathogenesis to
modulate the host immune response. Note: Although the three-dimensional structures of the analyzed sequences within the cell membrane are not
known, it might be assumed that these sequences may adopt a helical conformation upon membrane binding. Thus, helical wheel projections are
used for illustrative purposes only; the suggested mode of action does not depend on a particular secondary structure of the sequences.
Abbreviations: CKS-17, a synthetic retroviral envelope heptadecapeptide; Fr-MLV, Friend murine leukemia virus; gp, glycoprotein; HHV-6 U24, human
herpesvirus 6 U24 protein; HTLV-1, human T lymphotropic virus type 1; HVA, herpesvirus ateles; HVS, herpesvirus saimiri; ITAM, immunoreceptor
tyrosine-based activation motif; LASV, Lassa virus; LCMV, lymphocytic choriomeningitis virus; MARV, Marburg virus; MOPV, Mopeia virus; SARS-CoV,
severe acute respiratory syndrome coronavirus; SEBOV, Sudan Ebola virus; TACV, Tacaribe virus; Tip, tyrosine kinase interacting protein; Tio, two-in-
one protein; TMD, transmembrane domain; ZEBOV, Zaire Ebola virus.
doi:10.1371/journal.ppat.1000404.g002
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[35,36]. Recently, filoviral 17-mer pep-
tides corresponding to a 17–amino acid
domain in filoviral glycoproteins that
resembles an immunosuppressive motif in
retroviral envelope proteins have been
demonstrated to inhibit TCR-mediated
cell activation [37]. In all peptides, a
striking similarity is observed in the charge
distribution patterns with the positioning
of the essential positively charged residues
almost identical to that for the HIV gp41
FP (Figure 2E), suggesting again a similar-
ity in their mode of action. This clearly
demonstrates that different viruses have
adopted similar mechanisms of specifically
targeting TCR, disrupting receptor archi-
tecture, and suppressing the immune
system. Importantly, by virtue of the
acquired insight into this conserved struc-
tural motif, expanded predictions, hypoth-
eses, and conclusions can be derived to
being answering the question of whether
shared TCR-targeted strategies represent
a conserved function or a convergent
tactic of divergent viruses.
The generality of the SCHOOL model
suggests that TM interactions of other
MIRRs can also represent a point of viral
attack. As reported [38], the recognition of
the human CMV tegument protein pp65 by
NKp30, the natural killer (NK) cell-activat-
ing receptor, does not lead to NK cell
activation but instead results in a general
inhibition mediated by the dissociation of
the NKp30-f complex and a loss in the
ability of cells to kill virus-infected cells.
Within the context of the SCHOOL model,
pp65 may target the TM interactions
between NKp30 and f, leading to functional
disconnection of f in a manner similar to the
action of TCR CP and HIV FP (Figure 2).
TM interactions can be targeted not only
from outside but also from inside the cell.
Recently, it has been shown that the HHV-
6 U24 protein downregulates TCR surface
expression and that U24-expressing T cells
are resistant to activation by antigen-
presenting cells [39]. By controlling lym-
phocyte activation that is often accompa-
nied by herpesvirus reactivation, the virus
might prevent its own reactivation and
persist in a latent state, which is less prone
to immune recognition [39]. In this con-
text, U24 can serve to maintain equilibrium
between the virus and its host by keeping
HHV-6 titers low enough that they do not
cause massive immune activation [39].
TCR downregulation activity also has been
reported for the highly conserved mem-
brane-proximal sequence of the tyrosine
kinase-interacting protein (Tip) of HVS
[40,41]. Notably, primary sequences of
HHV-6 U2428–60 and HIV FP exhibit a
similar pattern with two Arg residues
spaced apart by eight amino acids
(Figure 2E). The positioning of the essential
electropositive residues is remarkably con-
served in HVS Tip213–228, the relevant
domain of the two-in-one (Tio) protein of
herpesvirus ateles (HVA) and HTLV-1
gp21 (Figure 2E). Thus, the SCHOOL
mechanisms similar to those applied for
TCR CP and HIV gp41 FP (Figure 2) can
be used by HHV-6 and other viruses in
their arsenal of immune evasion tactics.
Importantly, as predicted, the viral agents
prevent only antigen- but not antibody-
specific, T cell activation (Figure 2D).
Indeed, anti-CD3 antibodies activate
HHV-6-infected T cells, resulting in a large
increase of viral replication [42,43]. Inter-
estingly, increase of viral replication in-
duced by OKT3-mediated activation of
HIV-infected T cells is currently used for
purging of the latent HIV-1 reservoirs in
vivo [33], thus suggesting a potential
generality of the SCHOOL mechanism-
based antiviral approaches.
There are several important lessons that
we can learn from the molecular mecha-
nisms of viral pathogenesis. First, using
modern methodologies [44–51], it is
possible to design and produce TM agents
that are able to modulate the immune
response as specifically and effectively as
viruses
do. Second, as predicted, TCR CP and
many different immunomodulatory viral
sequences affect similar TCR–TM inter-
actions, suggesting that general principles
of designing TM peptides might be readily
used at this stage [47,48]. Third, antibod-
ies to MIRR signaling subunits can be
used to modulate the affected immune cell
response during viral infection. Fourth,
considering our selective ability to func-
tionally disconnect any particular TCR
signaling subunits [8,10,11,52], we can use
the relevant peptides as a powerful tool to
dissect fine mechanisms of viral pathogen-
esis. Finally, two unrelated viruses, HIV
and human CMV, use a similar mode of
action to modulate the host immune
response mediated by two functionally
different MIRRs, TCR and NKp30, thus
suggesting that similar general mecha-
nisms can be or are used by other viral
and possibly non-viral pathogens.
In conclusion, rather than targeting
virus-specific proteins or processes, it
would be advantageous to transfer thera-
peutic strategies that target redundant
processes found among a number of
viruses. In addition, as demonstrated by
the similar function of natural HIV FP and
synthetically derived clinically relevant
TCR CP, viral immune evasion strategies
can be transferred to therapeutic strategies
that require similar functionalities. Viruses
represent years of evolution and the
efficiency and optimization that come
along with it. Therefore, viral functions
should not only be studied as foreign
processes but as efficient strategies that we
can use in our own attempts at immune
evasion or immunomodulation.
Sequence Accession Numbers
Accession numbers (UniProtKB/Swiss-
Prot knowledgebase, http://www.expasy.
org/sprot/) for the viruses discussed in this
Opinion are: CMV, P06725; Fr-MLV,
P03390; HHV-6, Q69559; HIV-1, P04578;
HTLV-1; P03381; HVA, Q9YJQ8; HVS,
P22575; LASV, P08669; LCMV, P07399;
MARV, P35253; MOPV, P19240; SARS-
CoV, P59594; SEBOV, Q66814; TACV,
P18141; ZEBOV, Q05320.
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Table 1. Similarities in Characteristics and Immunomodulatory Activities of the T Cell
Receptor Core Peptide and HIV-1 gp41 Fusion Peptide.
Characteristics/Activation Model CP [17,24–26] FP [29]
Colocalization with TCR + +
Coprecipitation with TCR + +
Immunosuppressive activity in vivo + +
Inhibition of in vitro activation:
Antigen + +
Anti-TCRb antibody — ND
Anti-CD3 antibody — —
PMA/ionomycin — —
TCR, T cell receptor; CP, core peptide; FP, fusion peptide; ND, not determined; PMA, phorbol 12-myristate 13-
acetate.
doi:10.1371/journal.ppat.1000404.t001
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